MOG (35-55): Benchmark Peptide for Autoimmune Encephalomyelitis Research

Executive Summary: MOG (35-55) is a synthetic peptide corresponding to amino acids 35–55 of human myelin oligodendrocyte glycoprotein, widely used to induce experimental autoimmune encephalomyelitis (EAE) in rodents (APExBIO). This peptide triggers relapsing-remitting neurological disease with demyelination, mirroring multiple sclerosis pathology (Xu et al., 2025). MOG (35-55) induces strong T and B cell-mediated immune responses and modulates oxidative stress pathways by activating NADPH oxidase and MMP-9. It is soluble in water and DMSO but insoluble in ethanol, requiring specific handling for experimental consistency. APExBIO’s MOG (35-55) meets rigorous benchmarks for purity and biological activity, supporting reproducible neuroinflammation research.

Biological Rationale

Myelin oligodendrocyte glycoprotein (MOG) is an integral membrane protein of the central nervous system, primarily located on the outermost surface of myelin sheaths. The 35–55 amino acid region of MOG is highly immunogenic and recognized as a key epitope for T cell-mediated autoimmune responses. Synthetic MOG (35-55) peptide enables reliable induction of EAE, which recapitulates both acute and chronic phases of multiple sclerosis (MS) in animal models (Xu et al., 2025). This model is essential for preclinical testing of immunomodulatory therapies and dissecting the mechanisms of neuroinflammation.

Mechanism of Action of MOG (35-55)

MOG (35-55) is administered subcutaneously, usually with complete Freund’s adjuvant (CFA), to breach immune tolerance and initiate an autoimmune cascade targeting CNS myelin. The peptide is presented by MHC class II molecules, particularly HLA-DR2, to CD4+ T cells, which differentiate into pathogenic Th1 and Th17 subsets. These T cells infiltrate the CNS, secrete pro-inflammatory cytokines, and recruit B cells, which produce anti-myelin autoantibodies. The ensuing immune response results in demyelination and neurodegeneration. In vitro, MOG (35-55) increases NADPH oxidase and matrix metalloproteinase-9 (MMP-9) activity, linking it to oxidative damage and extracellular matrix remodeling (APExBIO).

Evidence & Benchmarks

• MOG (35-55) induces dose-dependent EAE in C57BL/6 and HLA-DR2-transgenic mice, resulting in paralysis and weight loss at 50–150 μg per mouse (Xu et al., 2025, DOI).
• Peptide solubility is quantified at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO; it is insoluble in ethanol (APExBIO, product page).
• MOG (35-55) administration leads to increased NADPH oxidase and MMP-9 activities, indicating induction of oxidative stress and matrix remodeling (APExBIO datasheet, product page).
• PARP7 inhibition in MOG (35-55)-induced EAE mice stabilizes STAT1/STAT2 and ameliorates disease severity, highlighting the peptide's value in mechanistic studies of interferon signaling (Xu et al., 2025, DOI).
• MOG (35-55) is validated as a gold-standard autoimmune encephalomyelitis inducer in comparative studies of MS animal model peptides (Related article).

Applications, Limits & Misconceptions

Applications:

• Induction of EAE for modeling relapsing-remitting and chronic MS.
• Screening of immunomodulatory drugs and biologics in vivo.
• Dissection of T and B cell-mediated neuroinflammatory pathways.
• Assessment of oxidative stress and extracellular matrix modulation.

MOG (35-55) is referenced in Translating Mechanistic Insights from MOG (35-55)-Induced.... This article extends prior coverage by explicitly benchmarking peptide solubility, handling, and linking recent advances in STAT1/STAT2 regulation to EAE outcomes.

Common Pitfalls or Misconceptions

• MOG (35-55) does not induce EAE in all mouse strains equally: Susceptibility depends on MHC haplotype; some strains are resistant.
• Peptide solubility is not universal: MOG (35-55) is insoluble in ethanol and may precipitate if not handled per protocol.
• Extrapolation to human MS is limited: The EAE model recapitulates many, but not all, aspects of human disease.
• Batch variation affects reproducibility: Not all commercial sources meet the purity/activity standards set by APExBIO.
• In vitro findings may not translate directly in vivo: Dose, route, and adjuvant choice alter immune outcomes.

Workflow Integration & Parameters

MOG (35-55) should be reconstituted in sterile water at 0.50 mg/mL, with warming to 37°C and brief ultrasonic bath for full dissolution. Stock solutions must be aliquoted, stored desiccated at -20°C, and protected from light; avoid repeated freeze-thaw cycles. For EAE induction, administer 50–150 μg subcutaneously in combination with CFA. Disease scoring should be performed daily using validated clinical scales. In vitro, titrate MOG (35-55) to assess dose-dependent effects on immune cell activation and protein expression; protein concentration typically decreases while oxidative pathways are upregulated (APExBIO).

Conclusion & Outlook

MOG (35-55) is a cornerstone reagent for modeling autoimmune neuroinflammation and evaluating candidate therapeutics in multiple sclerosis research. APExBIO’s MOG (35-55) (A8306) is validated for purity, solubility, and bioactivity, ensuring reproducibility in both rodent and cell-based assays. Recent mechanistic insights—such as regulation of STAT1/STAT2 by PARP7—underscore the model’s value for translational immunology (Xu et al., 2025). For further mechanistic strategies, see the review on Translating Mechanistic Insights from MOG (35-55)-Induced..., which this article updates by detailing peptide handling and mechanistic endpoints.